We provide experimental evidence that the systemic delivery of LNPs carrying oncosuppressor miRNAs strongly potentiates the antitumor efficacy of MAPKi therapy and blunts the development of drug resistance in BRAF-mutant melanoma xenografts. The gene discussed is BRAF; the disease is melanoma.